Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01870869
Recruitment Status : Terminated (There was no indication that long-term follow-up would differ between any of the studies that have evaluated devices within the 410 Style Matrix.)
First Posted : June 6, 2013
Results First Posted : June 22, 2020
Last Update Posted : June 22, 2020
Sponsor:
Information provided by (Responsible Party):
Allergan

Study Type Interventional
Study Design Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions Breast Augmentation
Breast Reconstruction
Breast Implant Revision
Intervention Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Enrollment 1951
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description Women who had breast augmentation with NATRELLE® 410 implants. Women who had revision of previous breast augmentation with NATRELLE® 410 implants. Women who had breast reconstruction with NATRELLE® 410 implants. Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Period Title: Overall Study
Started 288 206 1222 235
Completed 260 192 1092 205
Not Completed 28 14 130 30
Reason Not Completed
Implanted with nonstudy device             1             3             14             4
Death             0             0             7             1
Subject choice             6             2             22             8
Lost to Follow-up             10             2             25             3
Reason not Specified             1             2             20             4
Not evaluable             10             5             42             10
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction Total
Hide Arm/Group Description Women who had breast augmentation with NATRELLE® 410 implants. Women who had revision of previous breast augmentation with NATRELLE® 410 implants. Women who had breast reconstruction with NATRELLE® 410 implants. Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. Total of all reporting groups
Overall Number of Baseline Participants 278 201 1180 225 1884
Hide Baseline Analysis Population Description
Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.
Age, Continuous   [1] 
Mean (Full Range)
Unit of measure:  Years
Number Analyzed 277 participants 201 participants 1176 participants 223 participants 1877 participants
34.5
(18.0 to 63.0)
47.3
(20.0 to 79.0)
50.3
(21.0 to 79.0)
54.4
(31.0 to 80.0)
48.1
(18.0 to 80.0)
[1]
Measure Analysis Population Description: Number analyzed is the number of participants with available age data.
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 278 participants 201 participants 1180 participants 225 participants 1884 participants
Female
278
 100.0%
201
 100.0%
1180
 100.0%
225
 100.0%
1884
 100.0%
Male
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
1.Primary Outcome
Title Percentage of Participants According to Investigator Satisfaction With Implants
Hide Description The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: "Definitely satisfied" or "Somewhat satisfied" is reported.
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description:
Women who had breast augmentation with NATRELLE® 410 implants.
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Women who had breast reconstruction with NATRELLE® 410 implants.
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Overall Number of Participants Analyzed 77 34 247 52
Measure Type: Number
Unit of Measure: percentage of participants
Definitely satisfied 94.8 85.3 74.1 73.1
Somewhat satisfied 3.9 8.8 21.5 23.1
2.Primary Outcome
Title Percentage of Participants According to Participant Satisfaction With Implants
Hide Description The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: "Definitely satisfied" or "Somewhat satisfied" is reported.
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description:
Women who had breast augmentation with NATRELLE® 410 implants.
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Women who had breast reconstruction with NATRELLE® 410 implants.
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Overall Number of Participants Analyzed 77 34 247 52
Measure Type: Number
Unit of Measure: percentage of participants
Definitely satisfied 88.3 76.5 68.0 65.4
Somewhat satisfied 5.2 17.6 24.7 25.0
3.Secondary Outcome
Title Percentage of Participants With Local Complications
Hide Description Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Hide Outcome Measure Data
Hide Analysis Population Description
Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description:
Women who had breast augmentation with NATRELLE® 410 implants.
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Women who had breast reconstruction with NATRELLE® 410 implants.
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Overall Number of Participants Analyzed 278 201 1180 225
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
Any complication
6.62
(3.78 to 11.45)
9.09
(5.65 to 14.46)
14.50
(11.78 to 17.78)
10.19
(6.81 to 15.11)
Asymmetry
1.11
(0.26 to 4.73)
1.99
(0.75 to 5.21)
2.34
(1.59 to 3.44)
2.67
(1.21 to 5.84)
Breast pain
1.93
(0.51 to 7.15)
1.08
(0.15 to 7.39)
0.51
(0.23 to 1.13)
1.07
(0.26 to 4.30)
Capsular contracture
1.85
(0.68 to 4.98)
7.90
(3.57 to 17.01)
20.14
(8.90 to 41.85)
27.03
(9.04 to 64.93)
Delayed wound healing
0.00
(0.00 to 0.00)
0.50
(0.07 to 3.48)
0.34
(0.13 to 0.90)
1.78
(0.67 to 4.67)
Fluid accumulation/seroma
0.37
(0.05 to 2.57)
0.50
(0.07 to 3.48)
0.57
(0.26 to 1.28)
1.78
(0.67 to 4.67)
Hematoma
0.00
(0.00 to 0.43)
0.00
(0.00 to 0.00)
0.43
(0.18 to 1.04)
0.44
(0.06 to 3.11)
Hypertrophic scarring/other abnormal scarring
0.72
(0.18 to 2.85)
1.29
(0.32 to 5.12)
0.75
(0.24 to 2.30)
0.44
(0.06 to 3.11)
Implant extrusion
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
0.98
(0.40 to 2.38)
0.60
(0.08 to 4.17)
Implant malposition
2.21
(0.80 to 6.07)
1.00
(0.25 to 3.92)
1.22
(0.52 to 2.84)
1.33
(0.43 to 4.08)
Implant palpability/visibility
0.48
(0.07 to 3.33)
0.00
(0.00 to 0.00)
0.25
(0.08 to 0.79)
0.44
(0.06 to 3.11)
Implant rupture
2.14
(0.67 to 6.75)
6.15
(1.77 to 20.22)
2.03
(0.91 to 4.50)
3.84
(1.39 to 10.38)
Infection
0.36
(0.05 to 2.53)
1.49
(0.48 to 4.56)
1.21
(0.72 to 2.04)
3.18
(1.53 to 6.56)
Redness
0.00
(0.00 to 0.00)
0.50
(0.07 to 3.48)
0.83
(0.29 to 2.38)
3.31
(1.01 to 10.59)
Skin rash
0.36
(0.05 to 2.53)
0.00
(0.00 to 0.00)
0.08
(0.01 to 0.60)
0.00
(0.00 to 0.00)
Swelling
0.72
(0.18 to 2.85)
0.00
(0.00 to 0.00)
0.17
(0.04 to 0.68)
0.44
(0.06 to 3.11)
Tissue/skin necrosis
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
0.17
(0.04 to 0.68)
0.50
(0.07 to 3.51)
Upper pole fullness
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
0.44
(0.06 to 3.11)
Wrinkling/rippling
0.00
(0.00 to 0.00)
0.50
(0.07 to 3.48)
1.61
(0.78 to 3.33)
0.00
(0.00 to 0.00)
Other complications
1.46
(0.45 to 4.70)
2.99
(1.35 to 6.52)
4.37
(2.94 to 6.46)
1.43
(0.46 to 4.38)
4.Secondary Outcome
Title Percentage of Participants With Reoperations
Hide Description Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Hide Outcome Measure Data
Hide Analysis Population Description
Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description:
Women who had breast augmentation with NATRELLE® 410 implants.
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Women who had breast reconstruction with NATRELLE® 410 implants.
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Overall Number of Participants Analyzed 278 201 1180 225
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
13.02
(8.42 to 19.84)
25.08
(16.99 to 36.09)
39.70
(35.35 to 44.38)
35.75
(27.42 to 45.72)
5.Secondary Outcome
Title Percentage of Participants With Implant Removal With or Without Replacement
Hide Description Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Hide Outcome Measure Data
Hide Analysis Population Description
Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description:
Women who had breast augmentation with NATRELLE® 410 implants.
Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
Women who had breast reconstruction with NATRELLE® 410 implants.
Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Overall Number of Participants Analyzed 278 201 1180 225
Measure Type: Number
Number (95% Confidence Interval)
Unit of Measure: percentage of participants
7.17
(3.80 to 13.31)
19.09
(11.12 to 31.66)
19.54
(15.79 to 24.03)
20.59
(13.59 to 30.50)
Time Frame 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Adverse Event Reporting Description Adverse events were not collected in this study. Deaths are reported as Serious Adverse Events. Specific local complications were collected and are reported in the Outcome Measure section. Evaluable population.
 
Arm/Group Title Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Hide Arm/Group Description Women who had breast augmentation with NATRELLE® 410 implants. Women who had revision of previous breast augmentation with NATRELLE® 410 implants. Women who had breast reconstruction with NATRELLE® 410 implants. Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
All-Cause Mortality
Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/--   --/--   --/-- 
Hide Serious Adverse Events
Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/278 (0.00%)   0/201 (0.00%)   7/1180 (0.59%)   1/225 (0.44%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)         
Breast cancer  0/278 (0.00%)  0/201 (0.00%)  2/1180 (0.17%)  0/225 (0.00%) 
Metastatic carcinoma to liver  0/278 (0.00%)  0/201 (0.00%)  1/1180 (0.08%)  0/225 (0.00%) 
Recurrence of breast cancer  0/278 (0.00%)  0/201 (0.00%)  1/1180 (0.08%)  0/225 (0.00%) 
Liver cancer  0/278 (0.00%)  0/201 (0.00%)  0/1180 (0.00%)  1/225 (0.44%) 
Metastatic breast cancer  0/278 (0.00%)  0/201 (0.00%)  2/1180 (0.17%)  0/225 (0.00%) 
Respiratory, thoracic and mediastinal disorders         
Pulmonary hypertension  0/278 (0.00%)  0/201 (0.00%)  1/1180 (0.08%)  0/225 (0.00%) 
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Augmentation Revision-Augmentation Reconstruction Revision-Reconstruction
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/0   0/0   0/0   0/0 
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Therapeutic Area, Head
Organization: Allergan
Phone: 714-246-4500
EMail: clinicaltrials@allergan.com
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01870869    
Other Study ID Numbers: 410CAXL-001
First Submitted: June 4, 2013
First Posted: June 6, 2013
Results First Submitted: May 13, 2020
Results First Posted: June 22, 2020
Last Update Posted: June 22, 2020